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Abstract
Background: There is limited evidence on the course of health service costs before and after psychiatric 
inpatient treatment, which might also be affected by source of cost data. Thus, this study examines: i) 
differences in health care costs before and after psychiatric inpatient treatment, ii) whether these differences 
vary by source of cost-data (self-report vs. administrative), and iii) predictors of cost differences over time. 
Methods: Sixty-one psychiatric inpatients gave informed consent to their statutory health insurance 
company to provide insurance records and completed assessments at admission and 6-month follow-up. 
These were compared to the self‐reported treatment costs derived from the “Client Socio-demographic 
and Service Use Inventory” (CSSRI‐EU) for two 6‐month observation periods before and after admission 
to inpatient treatment to a large psychiatric hospital in rural Bavaria. Costs were divided into subtypes 
including costs for inpatient and outpatient treatment as well as for medication. 
Results: Sixty-one participants completed both assessments. Over one year, the average patient‐reported 
total monthly treatment costs increased from € 276.91 to € 517.88 (paired Wilcoxon Z = ‐2.27; P = 0.023). 
Also all subtypes of treatment costs increased according to both data sources. Predictors of changes in costs 
were duration of the index admission and marital status.
Conclusion: Self-reported costs of people with severe mental illness adequately reflect actual service use 
as recorded in administrative data. The increase in health service use after inpatient treatment can be seen 
as positive, while the pre-inpatient level of care is a potential problem, raising the question whether more 
or better outpatient care might have prevented hospital admission. Findings may serve as a basis for future 
studies aiming at furthering the understanding of what to expect regarding appropriate levels of post-
hospital care, and what factors may help or inhibit post-discharge treatment engagement. Future research 
is also needed to examine long-term effects of inpatient psychiatric treatment on outcome and costs.
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Implications for policy makers
• Inpatient treatment seems to motivate people with severe mental illness to seek more community treatment. A better coordination of community 
services after discharge might improve quality and efficiency of care and further increase community tenure.
• Self-reported costs of people with severe mental illness adequately reflect actual service use as recorded in administrative data. This means that 
people with severe mental illness are able to provide accurate information about service utilization. However, the conversion of self-reported 
utilization data to costs is laborious and its quality depends on the accuracy of unit costs. 
• The finding that length of inpatient stay predicted increase of certain subtypes of costs (outpatient services and medication) indicates that a 
better coordination of services for long-stay patients is necessary.
Implications for public
Health economic analyses are required to make informed and fair health care decisions. Their accuracy hinges upon the quality of cost data. 
However, the collection of cost data is laborious and sometimes not even possible because researchers do not have access to the funders’ records. 
This study examined whether inpatient mental health care, which is an expensive form of treatment, brings about a cost-offset. It was found that 
people with severe mental illness did not reduce utilization of health services after discharge. Rather, intensive long-term community care is 
required to avoid costly readmissions to hospital. Another main finding of this study was that self-reported cost data by and large correspond to 
data from administrative records provided by a health insurance company. This implies that self-report data provided by people with mental illness 
are a good basis for health economic analysis.
Key Messages 
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Background
Concern over growing healthcare costs has increased the 
pressure to develop cost-containment mechanisms such as 
disease management programs or integrated care (1,2). These 
are systemic approaches of managed care to reduce health 
care costs while keeping stable or even improving the quality 
of care. Integrated care, continuing care, and implementation 
of measurement-based care are successful approaches to 
improve patient outcome (3–6) with the potential to increase 
interest of mental health care providers in routine data 
collection and patient symptoms reporting (7).
Furthermore, costs might be saved and outcomes improved 
by substituting expensive inpatient services by appropriate 
outpatient and community services (1,8–10). A study in 
a primary care setting found that patient-centered care 
contributes to decreasing the use of health care resources 
and associated costs (11). It has also been shown that the 
integration of substance abuse treatment or mental health 
care into primary care contributes to a decrease of inpatient 
days and total medical costs (12,13). Furthermore, it has 
been found that a greater stability of care between patients 
with severe mental illness results in lower hospital costs and 
greater community costs (14).
In Germany, beginning with the mental health care reform 
in the 1970’s, there have been steps towards closing the 
gap between inpatient and outpatient mental health care 
by introducing community mental health services such as 
psychiatric day hospitals, implementing social psychiatric 
services and hospital-based outpatient services, and also 
by developing case management, managed care and other 
services to coordinate these services (15). Despite positive 
developments in community care, compared to other Western 
countries, inpatient treatment is still a mainstay of psychiatric 
treatment. Although the reduction of the number of 
psychiatric beds has led to a decrease of the mean duration of 
inpatient stays in hospitals for psychiatry and psychotherapy 
from 64.8 days in 1991 to 22.9 days in 2010, during the same 
period, numbers of people having received inpatient care 
nearly doubled from 406,910 (1991) to 805,287 (2010) (16), 
and the rehospitalization rate rose from 0.55 (1999) to 0.65 
(2002) (17). At the same time, health care costs for mental 
and behavioral disorders substantially increased in Germany 
during the last years (by 23% from 2002 to 2008 to € 28.6 
billion) (18).
This raises the question whether inpatient psychiatric 
treatment affects service utilization costs after discharge 
in the sense of the so-called cost-offset effect. Cost-offset 
suggests that the cost of inpatient treatment may be offset 
by a reduction in future general medical use and health care 
costs (19,20). Findings on cost-offset in mental health care 
are heterogeneous. A meta-analysis found that the strongest 
effect was in the reduction of inpatient rather than outpatient 
costs (21). Also older patients showed greater cost-offset 
effects (21,22). Von Korff and colleagues (23) found a cost-
offset in specialty mental health care for patients with major 
depression, but not for general medical services. Patients with 
diabetes and depression who received a stepped collaborative 
care intervention had greater mental health service costs, but 
non-mental health medication costs and other outpatient 
costs were lower. Another study found that treated anxious or 
depressed primary care patients with higher functional status 
had greater cost savings one year after the beginning mental 
health treatment (24). Also some other studies have reported 
a cost reduction after inpatient psychiatric treatment (25,26). 
However, it has also been argued that cost-offsets are unlikely 
in the treatment of people with severe mental illness, and that 
these patients may become more costly when they have more 
and adequate access to medical services (19,27). 
In sum, little is known about course of health care costs 
before and after inpatient mental health care, and whether 
cost changes over time are affected by source of cost data 
and patient characteristics. Thus, building on a previous 
paper which analyzed baseline data only (28), the present 
exploratory study will: i) examine differences in total 
and subtypes of health care costs (inpatient, outpatient, 
medication) before and after psychiatric inpatient treatment, 
ii) scrutinize whether these differences vary by source of cost 
data (self-report vs. administrative records), and iii) analyze 
predictors of cost differences over time.
Methods
Between September 2005 and March 2007, 507 adults with 
mental illness admitted to inpatient treatment at a large 
psychiatric hospital in rural Bavaria (Ulm University’s 
Clinic for Psychiatry and Psychotherapy II at Günzburg 
District Hospital) were asked to participate in the study 
“Outcome monitoring and outcome management in inpatient 
psychiatric care” (EMM, ISRCTN93197945) (29). Inclusion 
criteria were admission to inpatient psychiatric treatment, 
and age of 18-65 years. Exclusion criteria were a main 
diagnosis of organic mental disorder or substance abuse, 
and insufficient command of the German language. Patients 
received € 20 for participation in the study, and clinicians 
got a book voucher worth € 50. Of the 507 screened patients, 
141 (27.81%) refused to participate, and 72 (14.20%) did not 
meet the inclusion criteria. 294 (57.99%) patients gave written 
informed consent to participate in the study. Ninety-three 
(31.63%) of these were insured with a major statutory health 
insurance company (AOK Swabia), of which 82 (88.17%) 
additionally gave informed consent to the AOK Swabia to 
forward their insurance records to the EMM research team. 
The focus on insurees of the AOK Swabia was chosen for 
pragmatic reason because this is the insurance company 
covering the treatment costs of the largest number of patients 
receiving inpatient treatment at Ulm University’s Clinic for 
Psychiatry and Psychotherapy II, while other participants’ 
treatment costs were reimbursed by a large number (N = 20) 
other statutory or private health insurance companies. Figure 
1 gives an overview of flow of participants through the stages 
of the study.
Participants were interviewed by trained research workers 
at the hospital at admission (T0). For the assessment at six-
month follow-up (T1), the participant was either interviewed 
at home, or came to the hospital.
Measures
Socio-demographic data and service use
Patient socio-economic status and health service use were 
assessed via the German Version (30) of the “Client Socio-
demographic and Service Receipt Inventory – European 
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Version” (CSSRI-EU) (31) which is structured into five 
sections: i) Socio-demographic data; ii) Living situation; iii) 
Employment and income; iv) Service receipt: inpatient, day 
clinic, and outpatient service use; and v) Medication: name of 
drug, dosage form, prescribed daily dose, and frequency. The 
periods covered by the CSSRI were six months for inpatient 
service use, three months for outpatient service use, and one 
month for consumption of medication. Participants were 
asked at admission (T0) and at 6-month follow-up (T1) to 
complete the CSSRI-EU (see Figure 2).
Diagnosis and outcome
Diagnosis according to ICD-10 chapter V (32) was recorded by 
practitioners with advanced training in psychiatry or clinical 
psychology and entered into the hospitals documentation 
system. No structured clinical interview was used to confirm 
diagnoses. Diagnoses were grouped into schizophrenia (F2), 
affective disorders (F3), and other mental disorders (F4, F5, 
F6, and F7). Patient mental health was measured with the 
German version (33,34) of the Outcome Questionnaire 45 
(OQ-45.2) (35), which is a self-report measure widely used 
for outcome assessment in mental health services. The OQ-
45.2 contains 45 items (five-point Likert scale: never = 0, 
rarely = 1, sometimes = 2, often = 3, almost always = 4). The 
Total Score (TOT) is the prorated (less than 20% missing 
items) sum score of all items, with a higher score indicating 
more impairment.
Health service costs
First, self-reported health service costs were calculated 
by allocating unit costs to the service use data provided 
by the participants in the CSSRI (see above) for different 
types of costs (inpatient, outpatient, medication). Inpatient: 
Psychiatric inpatient service use was calculated by multiplying 
the number of inpatient days (excluding the day of discharge) 
by the hospital’s daily rate (€ 226.58). For day-clinic care, the 
hospital’s rate of € 140.73 was used for all treatment days. The 
daily rate for rehabilitation facilities for people with mental 
illness was € 105.30, and for somatic hospitals it was € 413.80 
Figure 1. Participant flow
Figure 2. Assessment of self-reported health service use
(36). Outpatient: Cost of treatment in psychiatric outpatient 
clinics were determined using the estimated average case 
value of € 210.00 per quarter (37). Costs for treatment by 
office-based psychiatrists and psychotherapists were defined 
using the contact values as fixed by their professional societies 
(€ 16.00 for psychiatrists and € 78.00 for psychotherapists) 
(38) multiplied by the number of contacts as reported by the 
patients. The same procedure was used for calculating the 
costs of treatment by physicians of other professional groups 
on the basis of the Unified Rating scale (EBM) of the National 
Association of Statutory Health Insurance Physicians 
(NASHIP) (39,40). Medication: On the basis of the patient-
reported use of medication during the observation period, 
costs of drugs were calculated using the “Red List” which is 
a widespread register for pharmaceutical drugs in Germany 
(41). The price per unit was derived from the price level for the 
largest package size (38). Then the unit price was multiplied 
by the prescribed daily dose and the number of prescription 
days. Furthermore, medications were divided into groups in 
order to derive costs for psychotropic drugs in addition to 
total costs for medications. 
Second, administrative records of health service costs were 
taken from the health insurance records which were reported 
for each quarter of a year. For each study participant, the AOK 
Swabia provided the costs for inpatient and day-clinic service 
use via Excel spreadsheets. Costs of outpatient services 
were obtained from the Physicians’ Association of Bavaria 
(KVB) through the AOK Swabia. Information on outpatient 
medication was also sent via Excel spreadsheets added by the 
complete records of prescribed recipes. 
Analysis
Analyses were carried out by using IBM SPSS Statistics, 
version 20. All costs were expressed in Euros. Given different 
time intervals for self-reported health services in the CSSRI, 
and different reporting periods in both cost data sources, the 
costs were converted into monthly costs. Missing values in the 
self-reported medication data, e.g. due to lack of daily dose 
information, were imputed by the respective mean value. Only 
the outpatient medication costs were included in the analysis 
since medication consumed during inpatient treatment are 
included in the inpatient daily costs. Total treatment costs 
per source were calculated by adding inpatient (including 
day-clinic) and outpatient costs, and costs for outpatient 
medication.
Enrolled (n=294)
Health insurance AOK Swabia 
(n=93)
Assessed for eligibility (n=507)
Granted access to AOK Swabia 
insurance records (n=82)
Excluded (n=213)
•Not meeting inclusion criteria (n=72)
•Refused to participate (n=141)
Health insurance other than 
AOK Swabia (n=201)
Refused access to AOK Swabia 
insurance records (n=11)
Participants (n=61)
No self-report cost data 
available (n=11)
Medi-
cation
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Outpatient pre
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In addition to mean and standard deviation, quartiles and 
range were used to report properties of cost data which 
were distinctly right skewed with values of zero occurring 
frequently. Differences between the observation periods 
T0 and T1, and differences between the two sources were 
determined by using the non-parametric paired Wilcoxon 
rank sum test. Furthermore, as recommended by Kilian and 
colleagues (42), multiple linear regression analyses with a 
bootstrap technique (2,000 replications) were conducted to 
ascertain the effects of independent variables (SES, and illness 
characteristics) on the differences between the observation 
periods T0 and T1 of both data sources for each group of costs 
as well as for total costs.
Results
Sample
Sixty-one participants completed both assessments and were 
no longer hospitalized at T1. As shown in Table 1, at study 
intake, participants were in their early forties, on average. 
Slightly more than half of them were female, and about one-
third lived alone. The majority had a low educational degree 
and over 60% were not in paid employment. As also shown, at 
study intake, the majority of participants received the primary 
diagnosis of an affective disorder. The mean length of index 
stay was six and a half weeks. A drop-out analysis showed 
that, compared to the participants with self-report only, this 
sample had a lower educational degree, and a shorter length 
of index stay.
Changes in health service costs over time by data source
Excluding the index admission, average total monthly 
treatment costs significantly increased over time in patient 
report as well as in administrative records (see Table 2 
and Table 3).
For subtypes of costs, a significant increase was found for 
medication and use of psychotropic drugs in both self-report 
and administrative records, but not for inpatient or outpatient 
service use. As shown in Table 4 and illustrated in Figure 3, 
the differences in total treatment costs between T0 and T1 
were independent of the data source which was also the case 
Table 1. Participants’ socio-demographic and clinical characteristics at admission
Administrative data and self-report 
(N = 61)
Self-report only
(N = 233)
Difference
Age, years; M (SD) 42.71 (12.20) 40.83 (11.90) F
(df = 292)
 = 1.19; P = 0.276
Length of index stay, days; M (SD) 46.75 (33.66) 63.91 (61.82) F
(df = 292)
 = 4.35; P = 0.044
OQ-45.2 TOT; M (SD) 77.18 (23.87) 79.52 (28.93) F
(df = 292)
 = 0.34; P = 0.562
Diagnosis: F2a; N (%) 18 (29.51) 67 (28.76) χ2(df = 2) = 0.17; P = 0.918
F3b; N (%) 33 (54.10) 132 (56.65)
F4, F5, F6, F7c; N (%) 10 (16.39) 34 (14.59)
Gender, female; N (%) 35 (57.38) 104 (44.64) χ2(df = 1) = 3.15; P = 0.085
Marital status: single; N (%) 23 (37.70) 102 (43.78) χ2(df = 2) = 0.89; P = 0.642
Married; N (%) 21 (34.43) 77 (33.05)
Otherd; N (%) 17 (27.87) 54 (23.18)
Educational level: high tracke; N (%) 4 (6.56) 34 (14.91) χ2(df = 2) = 15.76; P = 0.001
Middle trackf; N (%) 7 (11.47) 71 (31.14)
Low trackg; N (%) 50 (81.97) 123 (53.95)
Work: full-/part-time; N (%) 22 (36.07) 102 (44.93) χ2(df = 1) = 1.54; P = 0.214
Not working; N (%) 39 (63.93) 125 (55.07)
M = Mean; SD = Standard Deviation. Missing values on educational level (n = 5) and work (n = 6). a Schizophrenia, schizotypal and delusional disorders, 
b Affective disorders, c F4 = Neurotic, stress-related and somatoform disorders, F5 = Behavioral syndromes associated with physiological disturbances 
and physical factors, F6 = Disorders of adult personality and behavior, F7 = Mental retardation, d separated, divorced or widowed, e “Abitur”, f “Realschule”, 
“Hauptschule” or lower.
Table 2. Monthly costs in € of patient-reported health service use (N = 61)
M SD Range 25% Quantile Median 75% Quantile Differencea
Inpatient
T0 134.18 426.05 2265.80 0.00 0.00 0.00
Z = -0.78; P = 0.435
T1 272.23 792.55 3858.12 0.00 0.00 0.00
Outpatient
T0 93.68 117.84 720.72 16.00 57.39 131.32
Z = -1.22; P = 0.221
T1 120.37 166.86 1051.43 19.72 68.80 139.87
Medication
T0 49.05 79.25 318.48 0.00 0.00 82.26
Z = -3.96; P < 0.001
T1 125.29 198.89 1077.80 9.41 69.82 159.01
Psychotropic drugs
T0 43.92 73.80 318.48 0.00 0.00 54.83
Z = -4.30; P < 0.001
T1 115.91 172.89 1048.77 24.47 72.64 125.72
Totalb
T0 276.91 442.23 2417.04 51.34 112.18 296.30
Z = -2.27; P = 0.023
T1 517.88 812.82 3899.12 101.23 214.87 431.19
M = Mean; SD = Standard Deviation; a paired Wilcoxon rank sum test; b without costs for psychotropic drugs which are included in costs for medication.
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for each subtype of costs over time.
Prediction of changes over time in health service costs
Multiple linear regressions showed that none of the 
independent variables included in the models (gender, age, 
marital status, educational status, working status, length of 
index stay, as well as diagnosis and illness severity) predicted 
changes over time in self-reported total treatment costs 
and subtypes of costs for service use (inpatient services, 
medication, and psychotropic drugs). Table 5 shows that 
for outpatient costs, length of index stay was a significant 
predictor for changes in costs over time, i.e. with each extra 
day of index stay, the difference increased by € 2.35 per month. 
The model explained 21.15% of the variance in cost changes.
Five additional regressions tested the effect of the same 
predictors on changes over time for total treatment costs 
and subtypes of costs (inpatient and outpatient services, 
Table 3. Monthly costs in € as documented in health insurance records (N = 61)
M SD Range 25% Quantile Median 75% Quantile Differencea
Inpatient
T0 413.42 862.62 4427.96 0.00 0.00 333.87
Z = -1.66; P = 0.097
T1 849.78 1489.53 7020.65 0.00 0.00 1361.80
Outpatient
T0 93.20 85.72 499.34 45.23 65.53 120.79
Z = -0.52; P = 0.603
T1 102.71 88.18 424.62 46.81 76.26 117.02
Medication
T0 88.55 102.23 402.87 13.39 42.45 124.10
Z = -3.77; P < 0.001
T1 174.25 186.33 961.43 43.33 110.11 248.09
Psychotropic drugs
T0 63.51 84.69 292.55 0.00 18.27 105.84
Z = -3.66; P < 0.001
T1 141.24 175.04 833.83 27.09 70.68 212.23
Totalb
T0 595.16 927.49 4780.22 87.96 242.66 636.79
Z = -3.24; P = 0.001
T1 1126.75 1480.38 7018.30 248.28 426.20 1687.41
M = Mean; SD = Standard Deviation; a paired Wilcoxon rank sum test; b without costs for psychotropic drugs which are included in costs for medication.
Table 4. Differences in health service costs in € from T0 to T1 between self report and administrative records (N = 61)
M SD Range 25% Quantile Median 75% Quantile Differencea
Inpatient
SR 138.05 928.76 6123.92 0.00 0.00 0.00
Z = -0.91; P = 0.365
AR 436.36 1587.33 10304.01 -94.07 0.00 509.11
Outpatient
SR 26.69 194.40 1717.94 -53.06 13.01 64.31
Z = -0.17; P = 0.866
AR 9.52 95.75 647.07 -35.57 -2.06 42.07
Medication
SR 76.23 180.01 1200.20 0.00 44.65 96.67
Z = -0.26; P = 0.799
AR 85.71 183.02 1066.41 -9.06 44.18 111.13
Psychotropic drugs
SR 71.99 155.15 1052.25 0.00 49.70 100.10
Z = -0.58; P = 0.563
AR 77.72 176.87 979.99 -2.38 17.82 106.89
Totalb
SR 240.97 957.68 6184.60 -90.64 86.86 251.55
Z = -1.20; P = 0.229
AR 531.58 1550.34 10164.42 -27.27 147.96 522.83
M = Mean; SD = Standard Deviation; a paired Wilcoxon rank sum test; b without costs for psychotropic drugs which are included in costs for medication.
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Figure 3. Changes of monthly health service costs from T0 to T1 (N = 61)
medication and psychotropic drugs) of the administrative 
records yielding R2 values of 0.21, 0.24, 0.27, 0.41, and 0.40. 
Again, length of index stay (B = 2.55 and B = 2.72) significantly 
predicted change of costs over time for psychotropic drugs and 
medication. Furthermore, changes over time for outpatient 
service costs were significantly predicted by marital status, 
with monthly costs increasing by € 67.61 for participants who 
were married.
Discussion
The present study examined changes in health service costs 
during two 6-month observation periods before and after 
inpatient psychiatric treatment. Furthermore, differences 
between self-reported costs (SR) and administrative records 
(AR) were scrutinized.
Change of costs over time
This study found significant cost increases in total costs and 
costs for medication pre- and post-discharge. Also other 
subgroups of costs (inpatient and outpatient) increased, 
but changes did not reach statistical significance due to 
low sample size. This finding is in line with studies cited in 
a review of Olfson and colleagues showing that improved 
access to adequate services may increase treatment costs of 
people with severe mental illness (19).
Reasons for this are numerous, including heightened 
awareness of appropriate treatment options in the community 
through recommendations of key workers or other patients 
during inpatient treatment. After discharge, also caregivers 
might be motivated to take a closer look at the patient’s 
needs for care and support the uptake of targeted assistance. 
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Similarly, a study which evaluated health care services of 
former long-stay patients in Austria found that outpatient 
care entails significant cost savings, but in certain patients 
costs for outpatient care considerably exceeded expected 
hospitalization costs (43). Patients with more support needs 
caused higher costs, e.g. for accommodation in assisted 
living, full-time care, labor, and occupational therapies in 
sheltered workshops.
There is also evidence that prescription of newer and more 
expensive psychotropic medication in the hospital which is 
continuously consumed after discharge may lead to higher 
treatment costs (44,45). Furthermore, as a review showed, 
patients who took this newer psychotropic medication have 
a greater prevalence of medical co-morbidity concerning 
type 2 diabetes, higher lipid levels, and obesity which may 
increase the risk of cardiovascular diseases and hypertension 
(46), which in turn might contribute to higher treatment 
costs. However, this finding is only tentative, as it might take a 
longer period of time than the one-year follow-up interval in 
this study for people consuming newer antipsychotic drugs to 
develop such conditions. 
Predictors of cost changes
Regression analysis showed that the duration of the index 
psychiatric inpatients stay significantly predicted the pre-post 
difference of monthly self-reported outpatient service costs. 
The length of index stay was also a predictor for change over 
time of costs for psychotropic drugs and medication costs 
taken from the administrative records. This finding could, 
as above, indicate that a longer hospital stay stipulates more 
illness insight and acceptance of thorough treatment in the 
community. Furthermore, participants who are married had 
significant cost increases for monthly outpatient service costs 
of the administrative records. It can be assumed that marriage 
may be an indicator of positive social support that supports 
treatment engagement.
Self-report vs. administrative data
In line with studies elsewhere (11,14,46–49) it was found that 
inpatient treatment costs accounted for most of the overall 
expenditures, while the proportions differed by data source 
before (SR = 48.46% vs. AR = 69.46%), and after admission 
(SR = 52.57% vs. AR = 75.42%). Outpatient health service 
costs contributed the second largest share at T0 (SR = 33.83% 
vs. AR = 15.66%) while at T1, according to self-report, costs 
for medication and outpatient service were about equal 
(24.19% and 23.24% respectively). In administrative records, 
medication costs made up 15.46% of total costs, and outpatient 
health service costs only 9.12%.
Another important result is that no cost differences over 
time between the two data sources were found. In line with 
our previous work (28), this suggests that self-report data 
adequately measure the “real” costs of health service use over 
time as evident in the health insurance records of people 
with severe mental illness and supports their use in health 
economic analyses. 
Limitations
This study has a number of limitations. First, sample size was 
low so that many differences in changes of costs over time 
as well as between data sources (self-report vs. administrative 
data) may not have been detected. Second, collection of 
cost data may have produced bias. Self-reported cost data is 
subject to under-reporting (28), and the complex derivation 
of costs by allocating unit costs to self-reported service use 
is prone to imprecision, also because unit costs might not 
always reliably reflect actual costs. Third, administrative 
records were only available for the insurees of one statutory 
health insurance (AOK Swabia), and costs incurred by 
insurees of other statutory or private health insurance 
companies might be different. For a complete assessment of 
the study participants’ health insurance records, agreements 
would have had to be made with 20 other statutory or private 
health insurance companies which was not feasible. However, 
representativeness of the cost data from administrative 
records can be assumed to be reasonable, given that the AOK 
Swabia is responsible for the reimbursement of costs of the 
largest share of patients receiving psychiatric inpatient care 
at the clinic where the study took place. Fourth, explained 
variance was rather low in the models examining the pre-post 
differences of total and subtypes of treatment costs, suggesting 
there may be other explanatory variables not assessed in this 
study. Fifth, regarding the comparison between administrative 
and self-reported cost data, equivalence of the average cost per 
patient does not indicate complete congruence. Differences in 
the indication of any treatment and costs given any use may 
Table 5. Predictors of change over time in self-reported monthly outpatient service costs in € (multiple linear regression)
B SE P 95% CI
Constant 100.79 160.14 0.513 -219.239 – 437.855
Gendera Female -20.67 51.53 0.666 -146.474 – 57.296
Age Years 1.52 2.18 0.475 -1.983 – 6.810
Marital statusb
Married 0.79 82.29 0.991 -159.064 – 159.086
Other -37.32 60.56 0.522 -147.902 – 97.530
Educational levelc
Middle track -65.76 136.38 0.564 -405.598 – 160.688
Low track -40.04 123.71 0.671 -334.740 – 216.492
Workd Not working -28.03 53.49 0.609 -139.488 – 71.784
Diagnosis; ICD-10e
F2 -8.38 61.30 0.895 -122.567 – 120.913
Other 78.83 119.17 0.546 -117.676 – 336.135
Illness severity; OQ-45.2 TOT -2.32 1.49 0.152 -5.529 – 0.117
Length of index stay Days 2.35 0.82 0.024 1.011 – 4.287
Reference categories: a male; b single; c high track; d full-/part-time; e F3. R2 = 0.211; F = 1.195 (P = 0.316).
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result in similar average costs per person. Finally, due to the 
lack of a counterfactual, i.e. data on the “natural” flow of costs 
without inpatient treatment, findings do not allow a causal 
interpretation in the sense of an “effect” of inpatient treatment 
on course of costs. 
Conclusion
This study examined differences of health care costs before 
and after psychiatric inpatient treatment in people with mental 
illness. Total and subtypes of treatment costs increased after 
discharge from inpatient treatment. No cost differences over 
time between self-reported and administrative records were 
found suggesting that self-report data adequately measure the 
costs of health services in people with mental illness. 
Taken together, findings suggest a pattern of limited 
engagement in community treatment prior to hospitalization 
and more extensive engagement afterwards. The increase 
in health service use after inpatient treatment can be 
seen as positive, while the pre-inpatient level of care is a 
potential problem, raising the question whether more or 
better outpatient care might have reduced the likelihood of 
requiring hospital care. Findings may serve as a basis for 
future studies aiming at furthering the understanding of what 
to expect regarding appropriate levels of post-hospital care, 
and what factors may help or inhibit post-discharge treatment 
engagement. Future studies should also scrutinize differences 
over time between self-reported and administrative records of 
service use in larger samples of people with mental illness and 
other health conditions.
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